Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

Leukemia

Volumn 30, Issue 2, 2016, Pages 325-330

  Tambaro, F P ^a   Garcia Manero, G ^b   O'Brien, S M ^b   Faderl, S H ^c   Ferrajoli, A ^b   Burger, J A ^b   Pierce, S ^b   Wang, X ^b   Do, K A ^b   Kantarjian, H M ^b   Keating, M J ^b   Wierda, W G ^b  

^a SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; AZACITIDINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DECITABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RISK ASSESSMENT; ACUTE MYELOID LEUKEMIA; KARYOTYPE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; RETROSPECTIVE STUDY;

AGED; FEMALE; HUMANS; KARYOTYPE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES;

EID: 84959330438     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.227     Document Type: Article

References (20)

1. Wiernik PH. Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treat Options Oncol 2004; 5: 215-223.
2. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016-3024.
3. Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24: 2056-2062.
4. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-2460.
5. Colovic M, Suvajdzic N, Jankovic G, Tomin D, Colovic N, Fekete MD, et al. Therapyrelated myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. Biomed Pharmacother 2011; 65: 319-321.
6. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506-1514.
7. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-1438.
8. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, et al. Long-Term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
9. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
10. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapyrelated myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878-3884.
11. Robak T, Blonski JZ, Gora-Tybor J, Kasznicki M, Konopka L, Ceglarek B, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004; 40: 383-389.
12. Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-Term follow-up of US Intergroup Study E2997. Blood 2011; 118: 3525-3527.
13. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-Term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
14. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-Term follow-up of CALGB study 9712. J Clin Oncol 2011; 29: 1349-1355.
15. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, et al. Therapyrelated myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012; 25: 237-245.
16. Quintas-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; 14: 401-410.
17. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418-429.
18. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43-52.
19. Charafeddine KM, Ibrahim GY, Mahfouz RA, Zaatari GS, Salem ZM. Chronic lymphocytic leukemia associated with myelodysplastic syndrome with ring sideroblasts. South Med J 2010; 103: 823-827.
20. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389-4396.